Last reviewed · How we verify
NCT03479021
SPOT Vision Screening
trial testing Welch-Allyn Spot Vision Screener in Vision Disorders in 100 participants. Status unknown.
31 May 2019
Quick facts
| Lead sponsor | Children's Hospital Colorado |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 11 May 2017 |
| Primary completion | 31 May 2019 |
| Estimated completion | 31 May 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Welch-Allyn Spot Vision Screener
Conditions studied
- Vision Disorders — all drugs for Vision Disorders →
Sponsor
Children's Hospital Colorado
Who can join
Adults 4 to 17, any sex, with Vision Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this protocol is to determine if the Welch-Allyn Spot Vision Screener (SPOT) is effective at detecting various risk factors for poor vision in developmentally delayed children. These children have a higher percentage of vision disorders than the average population. The SPOT screen itself takes about six seconds to complete. It produces a photograph of the eye and a print out with amount of hyperopia, myopia, astigmatism and pupil size. The subject will have three SPOT screens around the time of their standard of care eye exam. The data obtained from the three SPOT screens will be compared among themselves for accuracy and to the findings of the clinical eye exam.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03479021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vision Disorders
Currently open trials in the same condition.
- NCT07085533 — Natural History Study of Inherited Retinal Diseases · recruiting
- NCT06992622 — Zhejiang Adolescent Spine and Vision Health Cohort: A Longitudinal Database Analysis · recruiting
- NCT06451172 — Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis · EARLY_PHASE1 · recruiting
- NCT04123626 — A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due · Phase 1, PHASE2 · active not recruiting
- NCT02911805 — Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation · NA · active not recruiting
Other Children's Hospital Colorado trials
Trials by the same sponsor.
- NCT07187245 — Feasibility of the Reality PAWS Program for Children in Isolation · NA · recruiting
- NCT07221006 — Impact of Facility Dog Intervention on Pediatric Patients · NA · not yet recruiting
- NCT06620289 — Impact of Dental Desensitization Facilitated by a Child Life Specialist Distress and Cooperation · enrolling by invitation
- NCT06283108 — Gurney Journey: Virtual Reality Distraction · NA · completed
- NCT06346106 — The Diagnostic Experience of Male Rett Syndrome · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03479021 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's Hospital Colorado
- Last refreshed: 23 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03479021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing